ADCTA vaccine

ADCTA (Autologous Dendritic Cell/Tumor Antigen) vaccine is an individualized, autologous dendritic cell-based immunotherapy developed by Safe Save Medical Cell Sciences & Technology. The vaccine is produced by co-culturing a patient's own dendritic cells with irradiated autologous tumor cells or pulsing them with tumor lysates and specific peptides. This process aims to prime the dendritic cells to present a broad array of tumor-associated antigens, such as WT-1, HER2, MAGE-A3, MAGE-A1, and gp100, to the immune system. Upon re-administration, the vaccine elicits antigen-specific CD4+ and CD8+ cytotoxic T cell responses and induces the secretion of interferon-gamma (IFN-γ) to target and eliminate cancer cells. It is primarily investigated as an adjuvant therapy for malignant gliomas, including recurrent glioblastoma multiforme (GBM), often in combination with standard chemoradiotherapy.

Other names

Autologous Dendritic Cell/Tumor Antigen vaccineADCTA-G vaccine